Advanced search
1 file | 1.98 MB Add to list

Serum levels of miR-126 and miR-223 and outcomes in chronic kidney disease patients

Author
Organization
Abstract
Several microRNAs (miRNAs) have been linked to chronic kidney disease (CKD) mortality, cardiovascular (CV) complications and kidney disease progression. However, their association with clinical outcomes remains poorly evaluated. We used real-time qPCR to measure serum levels of miR-126 and miR-223 in a large cohort of 601 CKD patients (CKD stage G1 to G5 patients or on renal replacement therapy - CKD G5D) from Ghent University Hospital and 31 healthy controls. All-cause mortality and cardiovascular and renal events were registered as endpoints over a 6 year follow-up period. miR-126 levels were significantly lower from CKD stage G2 on, compared to controls. The serum levels of miR-223 were significantly lower from CKD stage G3B on. When considering overall mortality, patients with levels of either miR-126 or miR-223 below the median had a lower survival rate. Similar results were observed for CV and renal events. The observed link between the two miRNAs' seric levels and mortality, cardiovascular events or renal events in CKD appears to depend on eGFR. However, this does not preclude their potential role in the pathophysiology of CKD. In conclusion, CKD is associated with a decrease in circulating miR-223 and miR-126 levels.
Keywords
SMOOTH-MUSCLE-CELLS, CIRCULATING MICRORNAS, PREDICTS PROGRESSION, INJURY MOLECULE-1, PLASMA, CANCER, QUANTIFICATION, PROLIFERATION, POPULATION, EXPRESSION

Downloads

  • s41598-019-41101-8.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 1.98 MB

Citation

Please use this url to cite or link to this publication:

MLA
Fourdinier, Ophélie, et al. “Serum Levels of MiR-126 and MiR-223 and Outcomes in Chronic Kidney Disease Patients.” SCIENTIFIC REPORTS, vol. 9, 2019, doi:10.1038/s41598-019-41101-8.
APA
Fourdinier, O., Schepers, E., Metzinger-Le Meuth, V., Glorieux, G., Liabeuf, S., Verbeke, F., … Metzinger, L. (2019). Serum levels of miR-126 and miR-223 and outcomes in chronic kidney disease patients. SCIENTIFIC REPORTS, 9. https://doi.org/10.1038/s41598-019-41101-8
Chicago author-date
Fourdinier, Ophélie, Eva Schepers, Valérie Metzinger-Le Meuth, Griet Glorieux, Sophie Liabeuf, Francis Verbeke, Raymond Vanholder, et al. 2019. “Serum Levels of MiR-126 and MiR-223 and Outcomes in Chronic Kidney Disease Patients.” SCIENTIFIC REPORTS 9. https://doi.org/10.1038/s41598-019-41101-8.
Chicago author-date (all authors)
Fourdinier, Ophélie, Eva Schepers, Valérie Metzinger-Le Meuth, Griet Glorieux, Sophie Liabeuf, Francis Verbeke, Raymond Vanholder, Benjamin Brigant, Anneleen Pletinck, Momar Diouf, Stéphane Burtey, Gabriel Choukroun, Ziad A Masst, and Laurent Metzinger. 2019. “Serum Levels of MiR-126 and MiR-223 and Outcomes in Chronic Kidney Disease Patients.” SCIENTIFIC REPORTS 9. doi:10.1038/s41598-019-41101-8.
Vancouver
1.
Fourdinier O, Schepers E, Metzinger-Le Meuth V, Glorieux G, Liabeuf S, Verbeke F, et al. Serum levels of miR-126 and miR-223 and outcomes in chronic kidney disease patients. SCIENTIFIC REPORTS. 2019;9.
IEEE
[1]
O. Fourdinier et al., “Serum levels of miR-126 and miR-223 and outcomes in chronic kidney disease patients,” SCIENTIFIC REPORTS, vol. 9, 2019.
@article{8609649,
  abstract     = {{Several microRNAs (miRNAs) have been linked to chronic kidney disease (CKD) mortality, cardiovascular (CV) complications and kidney disease progression. However, their association with clinical outcomes remains poorly evaluated. We used real-time qPCR to measure serum levels of miR-126 and miR-223 in a large cohort of 601 CKD patients (CKD stage G1 to G5 patients or on renal replacement therapy - CKD G5D) from Ghent University Hospital and 31 healthy controls. All-cause mortality and cardiovascular and renal events were registered as endpoints over a 6 year follow-up period. miR-126 levels were significantly lower from CKD stage G2 on, compared to controls. The serum levels of miR-223 were significantly lower from CKD stage G3B on. When considering overall mortality, patients with levels of either miR-126 or miR-223 below the median had a lower survival rate. Similar results were observed for CV and renal events. The observed link between the two miRNAs' seric levels and mortality, cardiovascular events or renal events in CKD appears to depend on eGFR. However, this does not preclude their potential role in the pathophysiology of CKD. In conclusion, CKD is associated with a decrease in circulating miR-223 and miR-126 levels.}},
  articleno    = {{4477}},
  author       = {{Fourdinier, Ophélie and Schepers, Eva and Metzinger-Le Meuth, Valérie and Glorieux, Griet and Liabeuf, Sophie and Verbeke, Francis and Vanholder, Raymond and Brigant, Benjamin and Pletinck, Anneleen and Diouf, Momar and Burtey, Stéphane and Choukroun, Gabriel and Masst, Ziad A and Metzinger, Laurent}},
  issn         = {{2045-2322}},
  journal      = {{SCIENTIFIC REPORTS}},
  keywords     = {{SMOOTH-MUSCLE-CELLS,CIRCULATING MICRORNAS,PREDICTS PROGRESSION,INJURY MOLECULE-1,PLASMA,CANCER,QUANTIFICATION,PROLIFERATION,POPULATION,EXPRESSION}},
  language     = {{eng}},
  pages        = {{12}},
  title        = {{Serum levels of miR-126 and miR-223 and outcomes in chronic kidney disease patients}},
  url          = {{http://doi.org/10.1038/s41598-019-41101-8}},
  volume       = {{9}},
  year         = {{2019}},
}

Altmetric
View in Altmetric
Web of Science
Times cited: